Defence Therapeutics Demonstrates Strong Preclinical in Vivo Efficacy Results Evaluating Accum-Kadcyla in Breast Cancer Models

Core Insights - Defence Therapeutics Inc. has announced promising preclinical in vivo results for its Accum®-Kadcyla, a novel version of Kadcyla® targeting HER2-positive breast cancer, showcasing a significant increase in anti-tumor efficacy [1][2][5] Study Results - Accum®-Kadcyla exhibited approximately a 20-fold increase in anti-tumor efficacy compared to Kadcyla® when administered at the same dose of 0.5 mg/kg, with significant tumor growth inhibition observed [2] - The study reported a durable and near-complete response in most mice treated with Accum®-Kadcyla, while Kadcyla® showed no effect at the same dosage [2] - All animals in the Accum®-Kadcyla group survived the study duration without signs of toxicity, indicating excellent tolerability [2] Implications for Patients and the Industry - The enhanced efficacy at lower doses could lead to reduced toxicity and side effects, addressing a major limitation of current ADC therapies, potentially allowing for a shift from second-line to first-line treatment options for patients [5][6] - The results validate the Accum® platform's ability to improve intracellular delivery and potency of ADCs by overcoming endosomal entrapment, thus enabling more efficient drug release and tumor killing [5][6] Next Steps and Commercial Outlook - Following these results, Defence Therapeutics plans to expand its Accum®-ADC program to additional HER2-positive and HER2-low tumor models and engage in discussions with potential pharmaceutical partners [7]